Johnson & Johnson (JNJ) Financials
Key financial figures for Johnson & Johnson (Q3 2026).
Johnson & Johnson Q3 2026 sales rose 5.9% to $25.4B, but GAAP EPS fell to $0.09 on a one-time talc litigation resolution charge and two M&A deals, and the company raised 2026 guidance. Reported sales were $25,399M, up 5.9% year over year (operational growth 6.0%, adjusted operational growth 6.1%). U.S. sales grew 9.1% to $14,959M and international grew 1.5% to $10,440M. Innovative Medicine sales were $16,757M, up 7.7% reported and 7.9% operational. The release credits TREMFYA, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, ERLEADA, SPRAVATO and CAPLYTA, partly offset by STELARA (about 690 basis points of drag). MedTech sales were $8,642M, up 2.5%, led by electrophysiology, Shockwave, contact lenses and trauma. On the outlook: 2026 guidance raised: estimated reported sales of $101.0B to $101.4B (midpoint $101.2B, +7.4%, versus $100.8B to $101.4B in the July 29, 2026 update); operational sales of $100.5B to $100.9B; adjusted operational sales growth of 6.4% to 6.8%; adjusted EPS of $11.05 to $11.15 (midpoint $11.10, +2.9%, versus $10.96 to $11.11 in the July 29, 2026 update); adjusted operational EPS of $10.95 to $11.05. Guidance excludes GAAP measures and uses a $1.15 euro rate. Figures are for Q3 2026, as Johnson & Johnson reported them.
- Revenue
- $25.4B
- Net Income
- $210M
- EPS
- $0.09
- Total Assets
- $197.4B
- Operating Cash Flow
- $7.7B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $25.4B | $210M | $0.09 | $6.4B | |
| Q2 FY2026 | $25.3B | $5.5B | $2.27 | $7.3B | |
| Q1 FY2026 | $24.1B | $5.2B | $2.14 | $1.5B | |
| Q4 FY2025 | $24.6B | $5.1B | $2.10 | $5.5B | |
| Q3 FY2025 | $24.0B | $5.2B | $2.12 | $8.4B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | $11.03 | $19.7B | |
| FY2024 | $88.8B | $14.1B | $5.79 | $19.8B | |
| FY2023 | $85.2B | $35.2B | $13.72 | $18.2B |
Frequently asked questions
What was Johnson & Johnson's revenue last quarter?
Johnson & Johnson reported revenue of $25.40 billion for Q3 FY2026, up 5.9% from the same period a year earlier.
Is Johnson & Johnson profitable?
Yes. Johnson & Johnson reported net income of $210.0 million for Q3 FY2026, a net margin of 0.83% on revenue.
How much free cash flow did Johnson & Johnson generate?
Johnson & Johnson generated free cash flow of $6.36 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Johnson & Johnson on SentiSense, with up to forty quarters and twenty fiscal years of history.